[Combined oral retinoid and PUVA therapy in the treatment of psoriasis and psoriatic arthropathy (author's transl)].
Combined oral retinoid (RO 10.9359) and PUVA therapy were given to 107 patients with psoriasis, 9 of whom had psoriatic arthropathy. Treatment was started with the retinoid at a dose of 1 mg/kg day and PUVA therapy added after 2 weeks. No other treatment was given. In 100 patients the combined therapy achieved clearing of the lesions, including scalp lesions, in a shorter time and with less total joules/cm2 than a group treated by PUVA alone. The remaining 7 patients were not responding to PUVA alone but achieved clearing when the retinoid was added. Five patients out of 9 with psoriatic arthropathy responded to the combined therapy. Predictable mild side-effects from the retinoid were encountered. The teratogenic risk of retinoid therapy is emphasized. The value of combined retinoid-PUVA therapy in psoriasis is discussed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D005050:Etretinate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy / Q000009:adverse effects; D010778:Photochemotherapy / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D014212:Tretinoin / Q000031:analogs & derivatives*
D014212:Tretinoin; D005050:Etretinate
Le rétinoäide aromatique associé à la photochimiothérapie pour le traitement du psoriasis et du rhumatisme psoriasique.